Worldwide COVID-19 cases drop by 17%, with deaths decreasing by 7%; Johnson & Johnson temporarily stopped COVID-19 vaccine production in the Netherlands; Amazon begins nationwide rollout of its telehealth service, Amazon Care.
The World Health Organization (WHO) announced a 17% decrease in global COVID-19 cases and a 7% decrease in global deaths over the week of January 31, compared with the previous week, as reported by The Associated Press. Worldwide, the agency reported more than 19 million new cases and less than 68,000 new deaths last week, with Omicron making up nearly 97% of cases. WHO’s weekly epidemiological report also noted that US cases dropped by 50%, however there was a 36% increase in cases in WHO’s eastern Mediterranean zone with notable increases in Afghanistan, Iran, and Jordan. For the most part, countries that experienced an early rise in Omicron cases are now seeing a decline in cases.
Johnson & Johnson (J&J) quietly paused production of its COVID-19 vaccine in the Netherlands at the end of 2021, according to The New York Times. With a stockpile of millions of existing vaccines, the J&J facility is now focusing on developing a vaccine for a different respiratory virus. The pause is expected to only last a month. However, the African Union and Covax—2 major customers of J&J that rely on the vaccines—are concerned about what this means for vaccination rates in lower-income countries.
Amazon announced Tuesday that it is rolling out its telehealth service Amazon Care on a national level, CNBC reported. Amazon Care was originally launched as a pilot program for employees at the company’s Seattle headquarters in 2019, providing both virtual and in-person health care. Amazon also said it will open brick-and-mortar health clinics in 20 US cities in 2022 as part of Amazon Care’s expansion. This news comes over a year after the company’s launch of Amazon Pharmacy in November 2020.
Real-World Data Demonstrate Efficacy of Beti-Cel Gene Therapy
November 28th 2024Investigators said patients experienced adverse effects in line with those expected for myeloablative conditioning with busulfan following treatment with betibeglogene autotemcel (beti-cel; Zynteglo; bluebird bio).
Read More
Expert Insights on How Utilization Management Drives Physician Burnout
November 26th 2024On this episode of Managed Care Cast, we speak with the author of a study published in the November 2024 issue of The American Journal of Managed Care® to explore the link between utilization management and physician burnout.
Listen
US ADHD Stimulant Shortage Highlights Growing Challenges in Adult Treatment
November 27th 2024While name brands like Adderall and Vyvanse may have been recently removed from the FDA Drug Shortage Database, it's unclear if it'll last; meanwhile, many generic forms of attention-deficit/hyperactivity disorder (ADHD) medication are still in short supply.
Read More